CYBN Stock Overview A clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Cybin Historical stock prices Current Share Price US$9.41 52 Week High US$19.85 52 Week Low US$6.50 Beta 0.92 1 Month Change -10.97% 3 Month Change 1.73% 1 Year Change -38.09% 3 Year Change -76.64% 5 Year Change n/a Change since IPO -64.31%
Recent News & Updates
New major risk - Shareholder dilution Nov 25
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Nov 19
No longer forecast to breakeven Nov 18
New minor risk - Share price stability Nov 13
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Nov 13
Cybin Inc. Announces Executive Appointments Oct 01 See more updates
New major risk - Shareholder dilution Nov 25
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Nov 19
No longer forecast to breakeven Nov 18
New minor risk - Share price stability Nov 13
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Nov 13
Cybin Inc. Announces Executive Appointments Oct 01
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones Sep 21
Insufficient new directors Sep 01
Forecast to breakeven in 2027 Aug 22 Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee
Cybin Inc., Annual General Meeting, Aug 27, 2024 Jul 06
Co-Founder recently bought US$64k worth of stock Jun 30
No longer forecast to breakeven Jun 27
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development Jun 13
Forecast to breakeven in 2027 Apr 01 Cybin Inc. announced that it has received $150 million in funding from a group of investors Mar 20
New minor risk - Profitability Mar 17
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder Mar 16
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder Mar 15
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design Mar 14 Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors Mar 13
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder Jan 23
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 Jan 09
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting Dec 07
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses Nov 30 Cybin Inc. has completed a Composite Units Offering in the amount of $30 million. Nov 15
New major risk - Revenue and earnings growth Nov 03
Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose Nov 01 Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).
New major risk - Shareholder dilution Oct 24
Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder Sep 22
Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million. Aug 30
Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial Aug 18
New major risk - Financial position Aug 15 Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million. Aug 03
Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder Jul 25
Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain Jul 23
Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct Jul 13
New minor risk - Share price stability Jul 05
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023 Jun 30
Cybin Inc., Annual General Meeting, Aug 29, 2023 Jun 27
Cybin Announces Scientific Management Transition Jun 06 Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC Jun 01
Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial May 25
Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial May 10
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004 Feb 02
Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain Jan 19
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004 Jan 13
Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs Jan 10
High number of new and inexperienced directors Nov 16
Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial Nov 11
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines Sep 21
Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder Aug 31
Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003 Aug 18
Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Jul 13
Independent Director recently bought US$56k worth of stock Jul 02
Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder Jun 28
Cybin Inc., Annual General Meeting, Aug 15, 2022 Jun 17
Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder Jun 10
Cybin Acquires DMT Clinical Study from Entheon Biomedical Jun 09
Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder Jun 01 Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain May 10
Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine May 06
High number of new and inexperienced directors Apr 27
Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Apr 14
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain Apr 01
High number of new and inexperienced directors Mar 31
Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial Mar 30
Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022 Jan 28
Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain Jan 12
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress Dec 01
Chief Operating Officer recently bought US$97k worth of stock Nov 26
Cybin Awards Grant for Psychedelic Treatment Clinic At Lenox Hill Hospital to Benefit Underserved Communities Nov 24
Chief Legal Officer recently bought US$54k worth of stock Aug 22
Cybin Files Two Additional International Patent Applications in Support of the Company’S Research Phase Programs Aug 20
Cybin Inc. Deleted from Other OTC Aug 06
Cybin Files its 13th Patent Application Jul 15
Cybin Announces Completion of Its 51St Pre-Clinical Psychedelic Molecule Study Jun 23
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy Jun 09
Cybin Inc. Files an International Patent Application Further Strengthening Its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions May 27
Cybin Inc. Files Its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms May 21
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder May 19
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 Apr 27 Shareholder Returns CYBN US Pharmaceuticals US Market 7D 3.9% -1.7% -2.6% 1Y -38.1% 3.2% 24.5%
See full shareholder returns
Return vs Market: CYBN underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is CYBN's price volatile compared to industry and market? CYBN volatility CYBN Average Weekly Movement 10.5% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CYBN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CYBN's weekly volatility (10%) has been stable over the past year.
About the Company Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
Show more Cybin Inc. Fundamentals Summary How do Cybin's earnings and revenue compare to its market cap? CYBN fundamental statistics Market cap US$176.41m Earnings (TTM ) -US$85.89m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CYBN income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$123.69m Earnings -CA$123.69m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 00:35 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cybin Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners David Martin Bloom Burton & Co. Sumant Satchidanand Kulkarni Canaccord Genuity
Show 6 more analysts 
